Catalent, a provider of advanced delivery technologies, development, and manufacturing solutions, agreed to acquire the manufacturing and packaging operations of Acorda Therapeutics, an American biotechnology company. Financial terms were not disclosed. "Catalent is a premier partner to companies working on multiple forms of inhaled drug delivery, from early-stage development to commercial-scale supply. This acquisition complements our existing U.S.-based capabilities in metered-dose and nasal inhalation by adding an experienced team of people and a premier facility enabling us to provide customers with extended capabilities for commercial-scale filling and packaging of dry powder inhalers,” Jonathan Arnold, Catalent President of Oral and Specialty Delivery.